These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
330 related articles for article (PubMed ID: 32474570)
1. Value and affordability of CAR T-cell therapy in the United States. Fiorenza S; Ritchie DS; Ramsey SD; Turtle CJ; Roth JA Bone Marrow Transplant; 2020 Sep; 55(9):1706-1715. PubMed ID: 32474570 [TBL] [Abstract][Full Text] [Related]
2. How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance? Huguet M; Raimond V; Kaltenbach E; Augusto V; Perrier L Bull Cancer; 2021 Dec; 108(12):1170-1180. PubMed ID: 34561025 [TBL] [Abstract][Full Text] [Related]
3. What CAR Will Win the CD19 Race? Quintás-Cardama A Mol Cancer Ther; 2019 Mar; 18(3):498-506. PubMed ID: 30824581 [TBL] [Abstract][Full Text] [Related]
4. Upsetting the apple CAR-T (chimeric antigen receptor T-cell therapy) - sustainability mandates USA innovation. Pantin J; Battiwalla M Br J Haematol; 2020 Sep; 190(6):851-853. PubMed ID: 32358811 [TBL] [Abstract][Full Text] [Related]
5. Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma. Lin JK; Muffly LS; Spinner MA; Barnes JI; Owens DK; Goldhaber-Fiebert JD J Clin Oncol; 2019 Aug; 37(24):2105-2119. PubMed ID: 31157579 [TBL] [Abstract][Full Text] [Related]
6. Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors. Alcantara M; Du Rusquec P; Romano E Oncoimmunology; 2020 Jun; 9(1):1777064. PubMed ID: 32934880 [TBL] [Abstract][Full Text] [Related]
7. Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Jain T; Bar M; Kansagra AJ; Chong EA; Hashmi SK; Neelapu SS; Byrne M; Jacoby E; Lazaryan A; Jacobson CA; Ansell SM; Awan FT; Burns L; Bachanova V; Bollard CM; Carpenter PA; DiPersio JF; Hamadani M; Heslop HE; Hill JA; Komanduri KV; Kovitz CA; Lazarus HM; Serrette JM; Mohty M; Miklos D; Nagler A; Pavletic SZ; Savani BN; Schuster SJ; Kharfan-Dabaja MA; Perales MA; Lin Y Biol Blood Marrow Transplant; 2019 Dec; 25(12):2305-2321. PubMed ID: 31446199 [TBL] [Abstract][Full Text] [Related]
8. The promise of CAR T-cell therapy in aggressive B-cell lymphoma. Nair R; Neelapu SS Best Pract Res Clin Haematol; 2018 Sep; 31(3):293-298. PubMed ID: 30213399 [TBL] [Abstract][Full Text] [Related]
9. Emerging vistas in CAR T-cell therapy: challenges and opportunities in solid tumors. Date V; Nair S Expert Opin Biol Ther; 2021 Feb; 21(2):145-160. PubMed ID: 32882159 [TBL] [Abstract][Full Text] [Related]
10. Challenges raised by the economic evaluation of CAR-T-cell therapies. The review by the French National Authority for Health. Raimond V; Kaltenbach E; Adam C; Lazzarotto S; Le Galès C; Perrier L; Wittwer J Bull Cancer; 2021 Dec; 108(12):1162-1169. PubMed ID: 34629167 [TBL] [Abstract][Full Text] [Related]
11. FDA-approved CAR T-cell Therapy: A Decade of Progress and Challenges. Ong MZ; Kimberly SA; Lee WH; Ling M; Lee M; Tan KW; Foo JB; Yow HY; Sellappans R; Hamzah S Curr Pharm Biotechnol; 2024; 25(11):1377-1393. PubMed ID: 39034731 [TBL] [Abstract][Full Text] [Related]
13. Advances in chimeric antigen receptor T cells. Beyar-Katz O; Gill S Curr Opin Hematol; 2020 Nov; 27(6):368-377. PubMed ID: 32925186 [TBL] [Abstract][Full Text] [Related]
14. Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy. Bouziana S; Bouzianas D Crit Rev Oncol Hematol; 2021 Jan; 157():103096. PubMed ID: 33181441 [TBL] [Abstract][Full Text] [Related]
15. Current Progress in CAR-T Cell Therapy for Solid Tumors. Ma S; Li X; Wang X; Cheng L; Li Z; Zhang C; Ye Z; Qian Q Int J Biol Sci; 2019; 15(12):2548-2560. PubMed ID: 31754328 [TBL] [Abstract][Full Text] [Related]